Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.17
+0.50000.97%
Post-market: 52.170.00000.00%16:58 EDT
Volume:1.84M
Turnover:95.50M
Market Cap:4.51B
PE:-11.55
High:53.08
Open:52.36
Low:51.15
Close:51.67
Loading ...

CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99

GuruFocus
·
15 Feb

CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment

GuruFocus
·
14 Feb

Medical AI Stocks Soar; CRISPR Rises 16%; Recursion Pharma Jumps 14%; Tempus AI up 5%

Tiger Newspress
·
14 Feb

CRISPR Therapeutics Ag : Morgan Stanley Raises Target Price to $32.00 From $30.00

THOMSON REUTERS
·
14 Feb

Crispr Therapeutics AG (CRSP) Gets a Sell from Morgan Stanley

TIPRANKS
·
14 Feb

Crispr Therapeutics Raised to Outperform From In-Line by Evercore ISI Group

Dow Jones
·
14 Feb

CRISPR Therapeutics Reports 2024 Results and Clinical Progress

TIPRANKS
·
14 Feb

Crispr Therapeutics Is Maintained at Hold by Stifel

Dow Jones
·
13 Feb

Crispr Therapeutics price target lowered to $49 from $53 at Stifel

TIPRANKS
·
13 Feb

Crispr Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks

TIPRANKS
·
13 Feb

Crispr Therapeutics AG: Advancements and Strategic Partnerships Justify Buy Rating

TIPRANKS
·
13 Feb

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
13 Feb

Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital

TIPRANKS
·
13 Feb

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday

Motley Fool
·
13 Feb

Crispr Therapeutics price target raised to $86 from $85 at BofA

TipRanks
·
12 Feb

CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates

Zacks
·
12 Feb

Crispr Therapeutics price target lowered to $48 from $53 at RBC Capital

TIPRANKS
·
12 Feb

Crispr Therapeutics price target raised to $120 from $100 at Truist

TIPRANKS
·
12 Feb

CRISPR Therapeutics Ag : TD Cowen Raises to Hold From Sell

THOMSON REUTERS
·
12 Feb